Courtney M Yuen1, Helen E Jenkins1, Carly A Rodriguez2, Salmaan Keshavjee3, Mercedes C Becerra4. 1. Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts; 2. Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts; and. 3. Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts; and Partners In Health, Boston, Massachusetts. 4. Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts; and Partners In Health, Boston, Massachusetts mbecerra@post.harvard.edu.
Abstract
BACKGROUND: Isoniazid has been the backbone of tuberculosis chemotherapy for 6 decades. Resistance to isoniazid threatens the efficacy of treatment of tuberculosis disease and infection. To inform policies around treatment of tuberculosis disease and infection in children, we sought to estimate both the proportion of child tuberculosis cases with isoniazid resistance and the number of incident isoniazid-resistant tuberculosis cases in children, by region. METHODS: We determined the relationship between rates of isoniazid resistance among child cases and among treatment-naive adult cases through a systematic literature review. We applied this relationship to regional isoniazid resistance estimates to estimate proportions of childhood tuberculosis cases with isoniazid resistance. We applied these proportions to childhood tuberculosis incidence estimates to estimate numbers of children with isoniazid-resistant tuberculosis. RESULTS: We estimated 12.1% (95% confidence interval [CI] 9.8% to 14.8%) of all children with tuberculosis had isoniazid-resistant disease, representing 120,872 (95% CI 96,628 to 149,059) incident cases of isoniazid-resistant tuberculosis in children in 2010. The majority of these occurred in the Western Pacific and Southeast Asia regions; the European region had the highest proportion of child tuberculosis cases with isoniazid resistance, 26.1% (95% CI: 20.0% to 33.6%). CONCLUSIONS: The burden of isoniazid-resistant tuberculosis in children is substantial, and risk varies considerably by setting. The large number of child cases signals extensive ongoing transmission from adults with isoniazid-resistant tuberculosis. The risk of isoniazid resistance must be considered when evaluating treatment options for children with disease or latent infection to avoid inadequate treatment and consequent poor outcomes.
BACKGROUND:Isoniazid has been the backbone of tuberculosis chemotherapy for 6 decades. Resistance to isoniazid threatens the efficacy of treatment of tuberculosis disease and infection. To inform policies around treatment of tuberculosis disease and infection in children, we sought to estimate both the proportion of childtuberculosis cases with isoniazid resistance and the number of incident isoniazid-resistant tuberculosis cases in children, by region. METHODS: We determined the relationship between rates of isoniazid resistance among child cases and among treatment-naive adult cases through a systematic literature review. We applied this relationship to regional isoniazid resistance estimates to estimate proportions of childhood tuberculosis cases with isoniazid resistance. We applied these proportions to childhood tuberculosis incidence estimates to estimate numbers of children with isoniazid-resistant tuberculosis. RESULTS: We estimated 12.1% (95% confidence interval [CI] 9.8% to 14.8%) of all children with tuberculosis had isoniazid-resistant disease, representing 120,872 (95% CI 96,628 to 149,059) incident cases of isoniazid-resistant tuberculosis in children in 2010. The majority of these occurred in the Western Pacific and Southeast Asia regions; the European region had the highest proportion of childtuberculosis cases with isoniazid resistance, 26.1% (95% CI: 20.0% to 33.6%). CONCLUSIONS: The burden of isoniazid-resistant tuberculosis in children is substantial, and risk varies considerably by setting. The large number of child cases signals extensive ongoing transmission from adults with isoniazid-resistant tuberculosis. The risk of isoniazid resistance must be considered when evaluating treatment options for children with disease or latent infection to avoid inadequate treatment and consequent poor outcomes.
Authors: D J Ulmasova; G Uzakova; M N Tillyashayhov; L Turaev; W van Gemert; H Hoffmann; M Zignol; K Kremer; T Gombogaram; J Gadoev; P du Cros; N Muslimova; A Jalolov; A Dadu; P de Colombani; O Telnov; A Slizkiy; B Kholikulov; M Dara; D Falzon Journal: Euro Surveill Date: 2013-10-17
Authors: I Bojorquez-Chapela; C E Bäcker; I Orejel; A López; A Díaz-Quiñonez; M I Hernández-Serrato; S Balandrano; M Romero; M M Téllez-Rojo Solís; M Castellanos; C Alpuche; M Hernández-Ávila; H López-Gatell Journal: Int J Tuberc Lung Dis Date: 2013-04 Impact factor: 2.373
Authors: J Lyu; M-N Kim; J W Song; C-M Choi; Y-M Oh; S D Lee; W S Kim; D S Kim; T S Shim Journal: Int J Tuberc Lung Dis Date: 2013-01 Impact factor: 2.373
Authors: N Martin-Casabona; F Alcaide; P Coll; J González; J M Manterola; M Salvadó; J A Caylà Journal: Med Clin (Barc) Date: 2000-10-21 Impact factor: 1.725
Authors: R C Brito; F C Q Mello; M K Andrade; H Oliveira; W Costa; H J Matos; M C Lourenço; V C Rolla; L Fonseca; A Ruffino Netto; A L Kritski Journal: Int J Tuberc Lung Dis Date: 2010-01 Impact factor: 2.373
Authors: Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon Journal: Clin Infect Dis Date: 2016-08-10 Impact factor: 9.079
Authors: Basel Karo; Anke Kohlenberg; Vahur Hollo; Raquel Duarte; Lena Fiebig; Sarah Jackson; Cathriona Kearns; Csaba Ködmön; Maria Korzeniewska-Kosela; Dimitrios Papaventsis; Ivan Solovic; Dick van Soolingen; Marieke J van der Werf Journal: Euro Surveill Date: 2019-03
Authors: J A Seddon; H E Jenkins; L Liu; T Cohen; R E Black; T Vos; M C Becerra; S M Graham; C Sismanidis; P J Dodd Journal: Int J Tuberc Lung Dis Date: 2015-12 Impact factor: 2.373